近年来，肿瘤-睾丸抗原（CTA）被认为是理想的肿瘤疫苗靶抗原而广泛用于肿瘤疫苗的研究，然而如何筛选合适的CTA却未见报道。我们前期研究发现：①NY-ESO-1可能与未成熟DC表面的TLR4/CRT复合体结合激活DC引起强烈的抗肿瘤免疫反应；②首次以大样本前列腺癌人群进行CTA筛查，结果显示NY-ESO-1、LAGE-1、SSX-2和XAGE-1在人前列腺血清高表达。本课题拟通过建立表达以上各种CTA的前列腺癌小鼠模型，研究它们参与肿瘤免疫应答的作用机制，选择其中免疫原性最强的CTA为疫苗靶抗原。同时提出假想：PAMPs或其模拟物与载体类佐剂联合运用能增强CTA的抗肿瘤效能。我们拟选用MF59和CpG ODN联合辅佐CTA，研究三者如何共同参与机体的抗肿瘤免疫应答，并探讨其机制。本课题的实施可望为肿瘤疫苗佐剂的选择提供新思路，为前列腺癌疫苗的研制提供新靶点。

Recently, Cancer-testis antigens are thought to be good candidate for target antigen in tumor vaccine, they have been used in tumor vaccine studies widely. However, there are seldom researches focused on how to screen appropriate CTAs. In our former study, we discovered that NY-ESO-1 may be recognized by TLR4/CRT complex in the surface of immature DC to stimulated DC to produce strong anti-tumor immune responses. In a CTA screening study with large sample of prostate cancer patients, we first discovered that 4 CTAs which were NY-ESO-1, LAGE-1, SSX-2 and XAGE-1 are highly expressed in the serum of prostate cancer patients. Our project will set up prostate cancer mouse model that expressed above CTAs to study the mechanism that how these CTAs are involved in the anti-tumor immune response, and to select the CTA with strongest immunogenicity to be the target antigen in tumor vaccine. We also postulated that pathogen-associated molecular patterns or their mimics together with vehicles can increase CTA's anti-tumor capability. Therefore we choose MF59 and CpG ODN as adjuvant for CTA to study the mechanism that how they are involved in the anti-tumor immune response together. It may give new evidence in how to choose appropriate tumor vaccine adjuvant and provide new target point in the research of prostate cancer vaccine.